Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat disease.